Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988066 | 1.00 | BRD4 (0.56) | BRD4RAB9ADRD3MCHR1LTA4H | |
| SCHEMBL29456002 | 0.81 | BRD4 (0.56) | BRD4AR | |
| SCHEMBL17477279 | 0.81 | BRD4 (0.40) | BRD4LTA4HHRH3KCNH2 | |
| SCHEMBL19160388 | 0.80 | NAMPT (0.40) | BRD4LTA4HHRH3 | |
| SCHEMBL20014332 | 0.80 | LTA4H (0.40) | BRD4LTA4HHRH3KCNH2 | |
| SCHEMBL29455909 | 0.80 | KDM4E (0.55) | BRD4RAB9ADRD3LTA4HHRH3 | |
| SCHEMBL3080285 | 0.79 | MCHR1 (0.57) | BRD4DRD3MCHR1HRH3AR | |
| SCHEMBL17477305 | 0.78 | BRD4 (0.53) | BRD4RAB9ALTA4H | |
| SCHEMBL29455917 | 0.78 | BRD4 (0.65) | BRD4MCHR1ARKCNH2 | |
| SCHEMBL22137697 | 0.77 | BRD4 (0.67) | BRD4DRD3MCHR1HRH3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| EP-3174881-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016618-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | BRD4 781/4885RAB9A 2573/4885DRD3 2302/4885 |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, BCL2 | BRD4 635/4885RAB9A 2307/4885DRD3 2618/4885 |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNI, CCNB1 | BRD4 816/4885RAB9A 2335/4885DRD3 2874/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | BRD4 4/4885RAB9A 1663/4885DRD3 2942/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | BRD4 781/4885RAB9A 2573/4885DRD3 2302/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | BRD4 781/4885RAB9A 2573/4885DRD3 2302/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | BRD4 6/4885RAB9A 3237/4885DRD3 1243/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | BRD4 781/4885RAB9A 2573/4885DRD3 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.